Locate Bio

Locate Bio’s LDGraft Granted FDA Breakthrough Device Designation

Programmed Drug Release of rhBMP-2 for Bone Healing

Locate Bio Closes £10 million Funding Round

Locate Bio appoints Keith Valentine as the Non-Executive Chair of the Board of Directors

Locate Bio raises £2.25m for new spinal treatments

Locate Bio announces the appointment of John von Benecke as CEO

Locate Bio receives £2.0 million investment from Mercia and the MEIF to expand its cell and gene therapy pipeline

Locate Therapeutics announces name change to Locate Bio and new investment from Mercia Technologies PLC